Aduro BioTech (NASDAQ:ADRO) posted its quarterly earnings results on Thursday. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.05), Fidelity Earnings reports. Aduro BioTech had a negative return on equity of 63.81% and a negative net margin of 784.73%. The company had revenue of $4.89 million for the quarter, compared to the consensus estimate of $4.56 million.
NASDAQ ADRO traded down $0.05 on Friday, hitting $1.35. The company’s stock had a trading volume of 341,152 shares, compared to its average volume of 389,110. Aduro BioTech has a 52-week low of $1.25 and a 52-week high of $8.10. The company has a debt-to-equity ratio of 0.29, a quick ratio of 9.11 and a current ratio of 9.11. The firm’s 50-day simple moving average is $1.57. The firm has a market capitalization of $108.05 million, a price-to-earnings ratio of -1.16 and a beta of 1.48.
Several equities analysts recently issued reports on ADRO shares. BidaskClub upgraded Aduro BioTech from a “sell” rating to a “hold” rating in a research report on Tuesday, April 30th. Svb Leerink restated an “outperform” rating and set a $9.00 price target on shares of Aduro BioTech in a research report on Monday, April 15th. Zacks Investment Research lowered Aduro BioTech from a “buy” rating to a “hold” rating in a research report on Tuesday, May 7th. Oppenheimer lowered Aduro BioTech from an “outperform” rating to a “market perform” rating in a research report on Monday, June 3rd. Finally, ValuEngine upgraded Aduro BioTech from a “sell” rating to a “hold” rating in a research report on Thursday. Five research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Aduro BioTech currently has an average rating of “Buy” and an average price target of $8.01.
Aduro BioTech, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation and dose expansion clinical trial and Phase Ib dose escalation and dose expansion clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase Ib/II clinical trial in combination with an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck.
Recommended Story: Does a trade war provide a risk to the global economy?
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.